Navigation Links
Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis
Date:9/26/2007

ical centers throughout North America, Australia, Latin America, and Europe, and will again compare alemtuzumab-treated patients to Rebif-treated patients according to two co-primary endpoints: the time to sustained accumulation of disability, and the annualized relapse rate. Alemtuzumab will be dosed at 12 mg/day for five days by daily IV infusion, with a second dosing 12 months later of 12 mg/day for three days. All patients will be followed from their entry into the trial until two years from the date that the last patient is randomized to treatment. Alemtuzumab-treated patients will continue to have safety evaluations for at least three years after the last course of treatment. The companies anticipate filing for marketing approval of alemtuzumab for the treatment of MS in 2011.

Alemtuzumab is an investigational drug for the treatment of MS and must not be used outside of a formal clinical trial setting in MS patients. Physicians or patients seeking additional information about the CARE-MS I trial should contact Genzyme Medical Information at 1-800-745-4447, option 2 in the United States, + 31 35 6991499 in Europe, or visit http://www.clinicaltrials.gov.

About Multiple Sclerosis

Multiple Sclerosis (MS) is a chronic disease of the central nervous system (CNS) in which the immune system can attack the brain and spinal cord. The disease causes a wide range of symptoms including fatigue, difficulty walking, numbness, and vision problems, and can progress to cause severe disability. Relapsing-remitting MS is the most common form of this disease.

About Alemtuzumab

Alemtuzumab is licensed in the United States as a single agent for the treatment of B-cell chronic lymphocytic leukemia (B-CLL), and outside of the U.S. for the treatment of B-CLL in patients who have been treated with alkylating agents and who have failed fludarabine therapy. The product was launched in its oncology indi
'/>"/>

SOURCE Genzyme Corporation; Bayer Schering Pharma AG
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
2. Genzyme Announces Results of Clinical Trial of Hylastan
3. Genzyme Announces Results of Clinical Trials Investigating Powder Form of Sevelamer Carbonate
4. Genzyme Announces Results of Clinical Trials Investigating Powder Form of Sevelamer Carbonate
5. Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year Alemtuzumab in Multiple Sclerosis Data Presented at AAN
6. Genzyme Announces Successful Completion of Study Investigating Sevelamer Carbonate in Patients With Chronic Kidney Disease
7. Schering-Plough Announces Hepatitis C Data Presentations at Digestive Disease Week (DDW) 2007 Annual Meeting
8. Schering-Plough Addresses Major Milestones and Challenges in Treatment of Patients With Chronic Hepatitis C
9. Schering-Plough Announces Presentation of Phase II Trial Results for Novel Oral Thrombin Receptor Antagonist at the 2007 Annual Meeting of The American College of Cardiology/i2 Summit
10. Sygnis Pharma AG announces date for presentation of clinical results
11. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... 2014 The report based on ... Share, Growth and Forecast, 2007 - 2017," elaborated by ... 20.8 billion in 2012 and is further expected to ... CAGR of 7.3% from 2012 to 2017. ... purposes, especially to prevent chronic diseases that may occur ...
(Date:9/30/2014)... , September 30, 2014 ... the CSF (Cerebrospinal Fluid) backflow of the Eldor spinal ... of the single hole pencil point spinal needles of ... Braun. Spinal anesthesia is an excellent type ... Orthopedics, Urology, General Anesthesia, etc. It is ...
(Date:9/30/2014)...   Acutus Medical, Inc. (ACM), a ... Cardiac Chamber Imaging and Dipole Density Mapping system to ... complex cardiac arrhythmias, including atrial fibrillation, announced it has ... imaging/mapping system as well as bring to market a ... to complete work on the AcQMap TM High ...
Breaking Medicine Technology:Nutraceutical Ingredient Market Will Reach USD 33.6 Billion Globally in 2018: Transparency Market Research 2Nutraceutical Ingredient Market Will Reach USD 33.6 Billion Globally in 2018: Transparency Market Research 3Nutraceutical Ingredient Market Will Reach USD 33.6 Billion Globally in 2018: Transparency Market Research 4Acutus Medical, Inc. Completes Additional $26.2M Series B Financing to Fund Portfolio Expansion 2Acutus Medical, Inc. Completes Additional $26.2M Series B Financing to Fund Portfolio Expansion 3
... When it comes to breast cancer, a physician,s ability ... of treatment depends on the quality of information revealed through ... the most advanced technology in breast cancer detection with positron ... PEM scanners in the Chicagoland area. Essentially, PEM ...
... BETHLEHEM, Pa., Nov. 1, 2011 Saladax Biomedical, Inc., ... assays to achieve the promise of personalized medicine for ... M.D., has accepted to chair the company,s scientific advisory ... as chief of the Division of Hematology/Oncology in the ...
Cached Medicine Technology:Palos Offers New Technology in the Fight Against Breast Cancer 2Saladax Biomedical, Inc. Names Edward Chu, M.D., Chair of the Company's Scientific Advisory Board 2Saladax Biomedical, Inc. Names Edward Chu, M.D., Chair of the Company's Scientific Advisory Board 3
(Date:9/30/2014)... Ohio (PRWEB) September 30, 2014 Life ... which provides CHL access to Life Length’s proprietary Telomere ... advanced and comprehensive telomere test on the market today, ... reports the percentage of short telomeres, providing the most ... Vice Chairman of the Department of Cell Biology at ...
(Date:9/30/2014)... Market Research Report on Global and ... in-depth market survey on Global and Chinese Cialis ... of Cialis including its classification, application and manufacturing ... top manufacturers of Cialis listing their product specification, ... The report further analyzes quantitatively 2009-2014 global and ...
(Date:9/30/2014)... 30, 2014 Catalent Pharma Solutions ... delivery technologies and development solutions for drugs, biologics ... agenda for the 25th Annual CPhI Worldwide Exhibition ... 6th to 9th. , Catalent is showcasing a ... during the show, including its facilities in China ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 ADOAMNI, ... first “crowdfunding” campaign through GoFundMe. The campaign, which surpassed ... for a portion of the funds necessary to convert ... for the Stockton Unified School District (SUSD). The campaign ... provide a portion of the funds necessary for the ...
(Date:9/30/2014)... The American Parkinson Disease ... supporting seven Research grants to junior investigators pursuing ... support post-doctoral scientists whose research training holds promise ... and treatment of Parkinson’s disease, and eight Centers ... medical centers across the country intended to strengthen ...
Breaking Medicine News(10 mins):Health News:Life Length® Announces New Partnership with Cleveland HeartLab® to Offer Telomere Technology in North America 2Health News:Life Length® Announces New Partnership with Cleveland HeartLab® to Offer Telomere Technology in North America 3Health News:Cialis Industry (CAS 171596-29-5) Global and Chinese Analysis for 2014-2019 Now Available at LifeScienceIndustryResearch.com 2Health News:Cialis Industry (CAS 171596-29-5) Global and Chinese Analysis for 2014-2019 Now Available at LifeScienceIndustryResearch.com 3Health News:Cialis Industry (CAS 171596-29-5) Global and Chinese Analysis for 2014-2019 Now Available at LifeScienceIndustryResearch.com 4Health News:Catalent Showcases Advanced Technologies and Supply Capabilities at CPhI Worldwide Conference and Exhibition 2Health News:Catalent Showcases Advanced Technologies and Supply Capabilities at CPhI Worldwide Conference and Exhibition 3Health News:ADOMANI Raises More Than 100,000 Dollars Through GoFundMe to Convert a School Bus 2Health News:ADOMANI Raises More Than 100,000 Dollars Through GoFundMe to Convert a School Bus 3Health News:The American Parkinson Disease Association Awards $1.1 million in Research Grants and Continues to Lead the Way to Ease the Burden – Find the Cure for Parkinson’s Disease 2Health News:The American Parkinson Disease Association Awards $1.1 million in Research Grants and Continues to Lead the Way to Ease the Burden – Find the Cure for Parkinson’s Disease 3Health News:The American Parkinson Disease Association Awards $1.1 million in Research Grants and Continues to Lead the Way to Ease the Burden – Find the Cure for Parkinson’s Disease 4
... reason for hope, experts say , , FRIDAY, Sept. 28 ... to treat the autoimmune disease lupus is building up ... an upbeat tone, researchers from across the United States ... Research Institute (LRI) of the improving outlook for patients ...
... The Branded Pharmaceutical,Association (BPA) represents specialty manufacturers, ... of the BPA produce,market or distribute Legacy ... drugs, with a history of safety and ... these products are manufactured in FDA licensed ...
... YORK, Sept. 28 According to the ... nearly one million Latinos received,physician-administered aesthetic procedures ... Flor Mayoral, a board certified,dermatologist in Miami, ... it is important that women make informed ...
... Senior Living,Inc. (NYSE: SRZ ) today announced ... being conducted by the Special Independent Committee of ... Sarbanes-Oxley,Section 404 internal control review efforts and provided ... Investigation As previously disclosed, in December 2006, ...
... Calif., Sept. 28 TJ Enterprises, LLC,announced ... a safe,alternative in the treatment of baby ... This comes after the U.S. Food and ... unopened,retail samples of a non-homeopathic gripe water, ...
... Care,Management Association (PCMA) released the following statement today,supporting ... the,House Energy and Commerce Subcommittee on Health: ... earlier,this week that would fix the flawed Average ... Reduction Act. "PCMA supports the decision to ...
Cached Medicine News:Health News:Better Lupus Treatments on the Horizon 2Health News:Better Lupus Treatments on the Horizon 3Health News:Better Lupus Treatments on the Horizon 4Health News:The Branded Pharmaceutical Association Comments on Hydrocodone 2Health News:Sunrise Provides Status Report on Special Independent Committee Investigation; Provides Updates on Management's Internal Control Review Efforts and on Legal Proceedings 2Health News:Sunrise Provides Status Report on Special Independent Committee Investigation; Provides Updates on Management's Internal Control Review Efforts and on Legal Proceedings 3Health News:Sunrise Provides Status Report on Special Independent Committee Investigation; Provides Updates on Management's Internal Control Review Efforts and on Legal Proceedings 4Health News:Sunrise Provides Status Report on Special Independent Committee Investigation; Provides Updates on Management's Internal Control Review Efforts and on Legal Proceedings 5Health News:Sunrise Provides Status Report on Special Independent Committee Investigation; Provides Updates on Management's Internal Control Review Efforts and on Legal Proceedings 6Health News:Sunrise Provides Status Report on Special Independent Committee Investigation; Provides Updates on Management's Internal Control Review Efforts and on Legal Proceedings 7Health News:Sunrise Provides Status Report on Special Independent Committee Investigation; Provides Updates on Management's Internal Control Review Efforts and on Legal Proceedings 8Health News:Sunrise Provides Status Report on Special Independent Committee Investigation; Provides Updates on Management's Internal Control Review Efforts and on Legal Proceedings 9Health News:Sunrise Provides Status Report on Special Independent Committee Investigation; Provides Updates on Management's Internal Control Review Efforts and on Legal Proceedings 10Health News:Sunrise Provides Status Report on Special Independent Committee Investigation; Provides Updates on Management's Internal Control Review Efforts and on Legal Proceedings 11Health News:Sunrise Provides Status Report on Special Independent Committee Investigation; Provides Updates on Management's Internal Control Review Efforts and on Legal Proceedings 12Health News:Sunrise Provides Status Report on Special Independent Committee Investigation; Provides Updates on Management's Internal Control Review Efforts and on Legal Proceedings 13Health News:Sunrise Provides Status Report on Special Independent Committee Investigation; Provides Updates on Management's Internal Control Review Efforts and on Legal Proceedings 14Health News:Sunrise Provides Status Report on Special Independent Committee Investigation; Provides Updates on Management's Internal Control Review Efforts and on Legal Proceedings 15Health News:After Infant Gripe Water Recall Scare, Homeopathic Medicine Offers Safe Alternative 2
The VPAP III ST is a complete system solution for SDB, providing comfortable and effective bilevel treatment with additional treatment modes. The VPAP III ST is an effective business solution for cli...
The GoodKnight® 425 Bi-Level® device is suitable for travel and includes features such as automatic altitude compensation, optional cigarette lighter adapter and portable battery pack...
... The BiPAP Pro with Bi-Flex bi-level ... time that the BiPAP Pro takes to ... includes Digital Auto-Trak Sensitivity™ which automatically triggers ... expiratory pressures based on the patients breathing ...
... Electrophoresis System (PGGE) is designed to ... density lipoproteins (LDL) and high density ... using nondenaturing pore gradient gel electrophoresis. ... short DNA sequencing runs. Temperature control ...
Medicine Products: